D
Dmitry V. Shcheblyakov
Researcher at Yahoo!
Publications - 36
Citations - 2507
Dmitry V. Shcheblyakov is an academic researcher from Yahoo!. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 9, co-authored 26 publications receiving 1214 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
Journal ArticleDOI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Olga V. Zubkova,Amir I Tukhvatullin,Dmitry V. Shcheblyakov,Alina S. Dzharullaeva,Daria M. Grousova,Alina S. Erokhova,Anna V. Kovyrshina,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Nadezhda L. Lubenets,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Morozova Lf,Elena A Smolyarchuk,Evgeny V Kryukov,Vladimir F Babira,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +31 more
TL;DR: The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants and was safe and well tolerated.
Journal ArticleDOI
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants.
Vladimir A. Gushchin,Inna V. Dolzhikova,Shchetinin Am,Alina S. Odintsova,Andrei E. Siniavin,Maria A. Nikiforova,Andrei A. Pochtovyi,Elena V. Shidlovskaya,Nadezhda A. Kuznetsova,Olga A. Burgasova,Liudmila V. Kolobukhina,Anna A. Iliukhina,Anna V. Kovyrshina,Botikov Ag,Aleksandra V. Kuzina,Daria M. Grousova,A. I. Tukhvatulin,Dmitry V. Shcheblyakov,Olga V. Zubkova,Oksana V. Karpova,Olga L. Voronina,Natalia N. Ryzhova,Ekaterina I. Aksenova,M.S. Kunda,Dmitry Lioznov,Daria Danilenko,Andrey Komissarov,Artem P. Tkachuck,Denis Y. Logunov,Alexander L. Gintsburg +29 more
TL;DR: In this paper, the authors evaluated the effect of the Sputnik V vaccine against the B.1.617 genotype in terms of virus neutralization and epidemiological efficacy.
Journal ArticleDOI
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Inna V. Dolzhikova,Olga V. Zubkova,A. I. Tukhvatulin,Alina S. Dzharullaeva,N. M. Tukhvatulina,Dmitry V. Shcheblyakov,Maxim M. Shmarov,Elizaveta A. Tokarskaya,Yana V. Simakova,Daria A. Egorova,D N Scherbinin,I. L. Tutykhina,A A Lysenko,Alexey V. Kostarnoy,Petya G. Gancheva,Tatiana A Ozharovskaya,B. V. Belugin,L. V. Kolobukhina,V. B. Pantyukhov,S. I. Syromyatnikova,I V Shatokhina,T. V. Sizikova,I. G. Rumyantseva,A. F. Andrus,N. V. Boyarskaya,A. N. Voytyuk,V. F. Babira,S. V. Volchikhina,D. A. Kutaev,A. N. Bel'skih,K. V. Zhdanov,S. M. Zakharenko,Borisevich Sv,Denis Y. Logunov,Boris S. Naroditsky,Alexander L. Gintsburg +35 more
TL;DR: The data indicate that the vaccine is safe and induces strong humoral and cellular immune response in up to 100 % of healthy adult volunteers, and provide a rationale for testing efficacy in Phase III trials.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
A. I. Tukhvatulin,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,T A Ozharovskaia,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Tatiana G. Zubkova,Konstantin A. Zakharov,Vasiliy B. Vasilyuk,Sergei V. Borisevich,B.S. Naroditsky,Denis Y. Logunov,Alexander L. Gintsburg +31 more
TL;DR: In this paper, a single-dose vaccine based on recombinant adenovirus type 26 (rAd26) vector carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein -Sputnik Light was developed.